RxDoctor Payments DataLook up a doctor →

Haresh Tharwani, MD

Psychiatry · Cary, NCNPI 1790869618

Payments from drug & device makers

$158,858in general payments, 2019–2025

Across 1,059 payments — averaging $150.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$70K
  • Alkermes, Inc.$36K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$31K
  • Otsuka America Pharmaceutical, Inc.$6K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
  • Neurocrine Biosciences, Inc.$3K
  • plus $9K from 27 others

What the payments were for

  • Consulting fees$17,27011%
  • Speaking & faculty fees$106,34567%
  • Travel & lodging$11,4307%
  • Food & beverage$23,66315%
  • Education$1510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,858 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$165,126
Medicare patients
142
Services billed
1,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$153,887
VraylarCariprazine Hcl36$70,845
TrintellixVortioxetine Hydrobromide38$32,441
AuvelityDextromethorphan Hbr/Bupropion25$22,847
BelsomraSuvorexant12$5,001
Desvenlafaxine Succinate ErDesvenlafaxine Succinate47$4,073
Memantine Hcl89$2,229
Clozapine27$1,950
Lamotrigine139$1,508
Duloxetine Hcl92$1,350
Clonazepam159$1,311
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$1,113
Trazodone Hcl95$1,038
Divalproex Sodium ErDivalproex Sodium24$1,015
Gabapentin106$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$2,955$153,88714 claims
AbbVieVraylar$70,306$70,84536 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$250$32,44138 claims
Axsome Therapeutics, Inc.Auvelity$214$22,84725 claims
Almatica Pharma LLCSertraline Hcl$314$67374 claims
Lilly USA, LLCOlanzapine$317$62435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →